Insulin Patch Pumps Market By Product Type (Disposable Patch Pumps, Reusable Patch Pumps), By Insulin Type (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), By Delivery Type (Basal, Bolus, Continuous Subcutaneous Insulin Infusion (CSII)), By Patient Population (Pediatric Patients, Adult Patients, Geriatric Patients), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), and By End User (Hospitals, Clinics & Diabetes Care Centers, Ambulatory Surgical Centers (ASCs), Home Care Settings),  Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Insulin Patch Pumps Market in the coming years?

The Insulin Patch Pumps Market accounted for USD 1.18 Billion in 2024 and USD 1.31 Billion in 2025 is expected to reach USD 3.72 Billion by 2035, growing at a CAGR of around 11.01% between 2025 and 2035. The insulin patch pump market is an area of the medical equipment market that delivers insulin to a group of diabetic patients in the shape of wearable, tubeless, skin-stickable pumps. They are small, handheld, and provide continuous subcutaneous insulin infusion (CSII), which is beneficial in stabilising the level of sugar in the blood more efficiently as compared to conventional injection techniques. They are particularly helpful when a person has type 1 diabetes and type 2 diabetes that is insulin-dependent. The market is being motivated by increasing levels of diabetes, innovation in technology, and the demand by patients to have more convenient and discreet forms of treatment. The most important players are such companies as Insulet Corporation, Tandem Diabetes Care, and Medtronic.

What do industry experts say about the Insulin Patch Pumps market trends?

“Patient selection is critical for successful endometrial ablation outcomes; it is best suited for women who have completed childbearing and require a non-hormonal solution for abnormal uterine bleeding.”

• Dr. Linda Bradley, MD – Professor of Obstetrics and Gynecology, Cleveland Clinic

“Endometrial ablation offers a minimally invasive alternative to hysterectomy for women with heavy menstrual bleeding, especially when medical therapy fails, reducing recovery time and surgical risk.”

• Dr. Jessica Shepherd, MD, FACOG – Gynecologist and Clinical Director, Baylor University Medical Center

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Insulin Patch Pumps market?

How does rising diabetes prevalence stimulate demand for patch pumps?

The increased rate of diabetes in the world market is one of the main factors that is increasing the demand for insulin patch pumps. The World Health Organisation estimates that there were more than 530 million adults living with diabetes as of 2021, which is a great deal higher than there were in previous decades. Metabolic syndrome has largely increased with changes in lifestyle, urbanisation, and sedentary behaviour. The prevalence of diabetes also records a sharp rise in countries such as India and the US, which have a growing number of patients in need of efficient insulin management.

Insulin patch pumps provide an easily accessible and discrete way to administer insulin continuously, and patients are more likely to regulate glucose levels, provided that adherence is much higher than when injecting insulin. They are an appealing alternative due to their ease of use and the fact that they are very comfortable and offer greater comfort to the patient, particularly those who have hectic schedules. With the increase in the number of diabetic patients, the need to develop new technologies of insulin delivery, such as patch pumps, which provide better treatment results and life quality, also increases.

Does increasing elderly population raise insulin management product requirements?

One of the major stimulating factors behind the growth of demand in insulin management products, such as the insulin patch pump, is the growing ageing population. Type 2 diabetes is more prevalent in older adults, and this requires good insulin delivery solutions. To illustrate the enormous disease burden among the elderly, the Centres for Disease Control and Prevention (CDC) indicates that approximately 26.8% of individuals who are aged 65 and above in the U.S. have been diagnosed with diabetes.

The Longitudinal Ageing Study (LASI) in India established that the prevalence of diabetes among elderly individuals is high, with 14% of the market comprising people aged 60 years and above, indicating the prevalence of diabetes in the elderly population. Insulin patch pumps are less invasive and more convenient compared to traditional injections and are especially useful with elderly patients, whose manual dexterity or adherence may be problematic. The increasing demand for innovative insulin management products is caused by the fact that this growing population of patients demands more user-friendly systems of insulin delivery.

Are limited reimbursement policies affecting adoption in emerging countries?

Low reimbursement plans are a major challenge to the manufacturers of insulin patch pumps in the developing nations. In low- and middle-income countries, like India and Bangladesh, the cost of diabetes treatment is mostly an out-of-pocket payment, and the high-tech devices, such as insulin patch pumps, are unaffordable to most people. The World Health Organisation states that more than 60% of the total health expenditure in these areas is out-of-pocket, so patients are unable to afford new treatment options.

The study that was issued by the International Diabetes Federation indicates that in emerging economies, government health schemes fail to provide high-end insulin delivery mechanisms, and the adoption rates are low. The high cost share that patients pay is prohibitive even in the presence of partial reimbursement. Such financial deprivation postpones the use of modern instruments of diabetes management, thus leading to poor glycaemic control and predisposing the patient to complications.

Will smart integration with apps drive personalized diabetes care solutions?

The personalised management of diabetes is being redefined through smart combinations of insulin patch pumps and mobile applications, allowing real-time glucose monitoring, automated insulin doses, and specific feedback according to personal habits. The CDC estimates that almost 37 million Americans are living with diabetes, and the use of continuous glucose monitoring and smart insulin delivery can enhance the level of glycaemic control and decrease hospitalizations. The NIDDK research indicates that the outcomes and adherence of patients can be improved with the use of digital tools and insights by providing them with personalised insights and timely interventions.

The technologies also promote effective communication between patients and healthcare providers so that they can manage them proactively. The convenience of data exchange with the help of apps aids in the timely identification of complications and decreases future medical expenditures. To enable more efficient diabetes management, insulin patch pumps with app integration are a new step in empowering patients, as medical programmes sponsored by governments actively encourage these types of technologies.

Can untapped Asia-Pacific markets unlock major expansion possibilities soon?

The insulin patch pump market has good prospects in untapped Asia-Pacific markets since the prevalence of diabetes in the region is high and increasing. The International Diabetes Federation (IDF) has reported that at present, the Western Pacific area, such as China, Japan, and Australia, harbours more than 200 million adults with diabetes. In India, according to the National Family Health Survey (NFHS-5), about 8% of adults have diabetes, and most of them are not even diagnosed due to a lack of healthcare facilities in rural regions.

Governments are now paying more attention to better management of diabetes by developing more healthcare facilities and raising awareness, like the Healthy China programme in China, which focuses on the control of non-communicable diseases. With the difficulties in the management of the disease and underserved groups, insulin patch pumps, with their ease of use and constant insulin delivery, can also be of great help in enhancing adherence to the treatment. All these factors render the Asia-Pacific region one of the major regions where technologies of insulin patch pumps can be adopted and extended.

What are the key market segments in the Insulin Patch Pumps industry?

Based on the product type, the Insulin Patch Pumps Market has been classified into Disposable Patch Pumps, Reusable Patch Pumps. The most visible in the insulin patch pump market is the disposable patch pump segment. This is mainly because they are convenient and easy to use, and they have fewer risks of being infected, and thus they are mostly preferred by patients who do not want hassles related to insulin delivery without having to maintain the devices.

With disposable pumps, there is no need to clean or refill the pump regularly, which helps create a more convenient experience. Their subsequent spread is also due to the technological progress and the rising awareness of managing diabetes, as the leading type of product in this market is the disposable patch pump.

 Based on the Insulin Type, the Insulin Patch Pumps Market has been classified into Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Long-acting Insulin, and Premixed Insulin. The most notable part of insulin patch pumps is the rapid-acting insulin part. This is because the rapid-acting insulin has a rapid rate of action, and the rate of action is almost identical to the response of the natural insulin of the body to meals, and suitable for the management of the blood glucose level after meals.

Insulin patch pumps mainly administer fast-acting insulin to allow high precision and at the right time glucose regulation, and avoid hypoglycaemia. The rising incidence of diabetes and the requirement for efficient, convenient administration schemes of insulin also spur the supremacy of rapid-acting insulin in this group.

Which regions are leading the Insulin Patch Pumps market, and why?

The North American insulin patch pump market is growing owing to several factors. Diabetes prevalence in the area is high due to lifestyle trends and ageing populations, and this has augmented the need to find viable methods of managing diabetes. Good healthcare facilities, the embracing of newer medical technologies, and good reimbursement policies also contribute to the development of this market. The existence of large market players and continuous research and development efforts gives rise to fast innovation and product availability.

Consumer awareness about insulin patch pumps and their convenience over traditional methods further drives adoption. The regulatory environment of the region is also relatively favourable, with quicker approvals and entry. Moreover, the further promotion of the activity of the government in the sphere of diabetes treatment and the augmentation of the number of people receiving healthcare services contribute to the growth of the market. All these reasons make North America a market leader in the insulin patch pump market globally.

The Asia Pacific insulin patch pumps market is expanding owing to a number of convergent factors. The increasing number of diabetic patients, especially in such nations as China and India, is fuelling the need to seek a superior diabetes management system. The increased medical consciousness and the facilitation of access to medical technologies are promoting the use of wearable insulin delivery systems. Healthcare infrastructure is being more and more invested in by governments and by the private sector, which contributes to the further development of the market.

The affordability of manufacturing possible in the region compels world companies to establish manufacturing and research, and development structures. The rising number of middle-class citizens with rising disposable income is also more open to using innovative medical equipment that is easy to use. The high number of domestic and foreign medical device manufacturers makes the market penetration easy. These factors together position the Asia Pacific region as a significant growth hub for insulin patch pumps.

What does the competitive landscape of the Insulin Patch Pumps market look like?

In the insulin patch pump market, there is a growing intensity where major firms are working towards innovation and product diversification to benefit patients in terms of convenience and management of diabetes. The major stakeholders, such as Insulet Corporation, Medtronic, and Tandem Diabetes Care, have led the way by incorporating new technology like continuous glucose and automated insulin delivery algorithms.

Such recent strategic actions as the acquisition by Medtronic of a smaller developer of patch pumps to enhance its offerings of tubeless pumps and the efforts of Embecta to obtain regulatory approvals for new disposable insulin delivery systems are some of the recent strategic moves of the companies. There is an increased market interest in newer regions and places such as Asia, where joint ventures and domestic production activities are serving to enhance accessibility.

As the reimbursement policies are changing and technology is advancing at a high pace, firms are competing to have better options that are easier to use, more precise, and cost-effective, and by doing so, the market is poised to grow endlessly in the next few years.

Insulin Patch Pumps Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Insulin Patch Pumps industry?

• In November 2024, Embecta announced it would discontinue its patch pump program, despite having FDA clearance. The decision was part of a broader restructuring effort. It aimed to focus on financial stability and strengthen core business operations.
• In September 2024, Embecta received FDA 510(k) clearance for its disposable, tubeless insulin patch pump. The device included a 300-unit insulin reservoir. It was designed to meet the needs of both Type 1 and Type 2 diabetes patients.

Report Coverage:

By Product Type

• Disposable Patch Pumps
• Reusable Patch Pumps

By Insulin Type

• Rapid-acting Insulin
• Short-acting Insulin
• Intermediate-acting Insulin
• Long-acting Insulin
• Premixed Insulin

By Delivery Type

• Basal
• Bolus
• Continuous Subcutaneous Insulin Infusion (CSII)

By Patient Population

• Pediatric Patients
• Adult Patients
• Geriatric Patients

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By End User

• Hospitals
• Clinics & Diabetes Care Centers
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Insulet Corporation
• Medtronic plc
• Tandem Diabetes Care, Inc.
• CeQur SA
• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• Microtec Medical Ltd
• ViCentra B.V.
• SOOIL Development Co., Ltd.
• EOFLOW Co., Ltd.
• Valeritas Inc.
• Cellnovo Group SA
• Debiotech SA
• Embecta Corp.
• Medtrum Technologies

Frequently Asked Questions (FAQs)